Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia
Identifieur interne : 003B38 ( Main/Exploration ); précédent : 003B37; suivant : 003B39Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia
Auteurs : Charles H. Adler [États-Unis] ; Stephen F. Bansberg [États-Unis] ; Kari Krein-Jones [États-Unis] ; Joseph G. Hentz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-09.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Bontoxilysin, Botulinum Toxins (administration & dosage), Botulinum Toxins (therapeutic use), Dose-Response Relationship, Drug, Female, Humans, Injections, Male, Middle Aged, Nervous system diseases, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Safety, Severity of Illness Index, Spastic dysphonia, Vocal Cords (physiopathology), Voice Disorders (diagnosis), Voice Disorders (drug therapy), Voice Disorders (physiopathology), botulinum toxin type B, dystonia, spasmodic dysphonia.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Neuromuscular Agents.
- diagnosis : Voice Disorders.
- drug therapy : Voice Disorders.
- physiopathology : Vocal Cords, Voice Disorders.
- Adult, Dose-Response Relationship, Drug, Female, Humans, Injections, Male, Middle Aged, Severity of Illness Index.
Abstract
This single‐site, open‐label, dose‐finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT‐B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from −3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (± standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (±1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT‐B is safe and effective for the treatment of adductor spasmodic dysphonia. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20098
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A52
- to stream Istex, to step Curation: 001A52
- to stream Istex, to step Checkpoint: 002519
- to stream PubMed, to step Corpus: 003351
- to stream PubMed, to step Curation: 003351
- to stream PubMed, to step Checkpoint: 003314
- to stream Ncbi, to step Merge: 000F37
- to stream Ncbi, to step Curation: 000F37
- to stream Ncbi, to step Checkpoint: 000F37
- to stream Main, to step Merge: 005496
- to stream PascalFrancis, to step Corpus: 002080
- to stream PascalFrancis, to step Curation: 000C41
- to stream PascalFrancis, to step Checkpoint: 002007
- to stream Main, to step Merge: 005845
- to stream Main, to step Curation: 003B38
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia</title><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name></author><author><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F." last="Bansberg">Stephen F. Bansberg</name></author><author><name sortKey="Krein Ones, Kari" sort="Krein Ones, Kari" uniqKey="Krein Ones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4B96E5B2013281C64D41647F88951029FF0AB0DF</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20098</idno><idno type="url">https://api.istex.fr/document/4B96E5B2013281C64D41647F88951029FF0AB0DF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A52</idno><idno type="wicri:Area/Istex/Curation">001A52</idno><idno type="wicri:Area/Istex/Checkpoint">002519</idno><idno type="wicri:doubleKey">0885-3185:2004:Adler C:safety:and:efficacy</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15372600</idno><idno type="wicri:Area/PubMed/Corpus">003351</idno><idno type="wicri:Area/PubMed/Curation">003351</idno><idno type="wicri:Area/PubMed/Checkpoint">003314</idno><idno type="wicri:Area/Ncbi/Merge">000F37</idno><idno type="wicri:Area/Ncbi/Curation">000F37</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F37</idno><idno type="wicri:doubleKey">0885-3185:2004:Adler C:safety:and:efficacy</idno><idno type="wicri:Area/Main/Merge">005496</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0549404</idno><idno type="wicri:Area/PascalFrancis/Corpus">002080</idno><idno type="wicri:Area/PascalFrancis/Curation">000C41</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002007</idno><idno type="wicri:doubleKey">0885-3185:2004:Adler C:safety:and:efficacy</idno><idno type="wicri:Area/Main/Merge">005845</idno><idno type="wicri:Area/Main/Curation">003B38</idno><idno type="wicri:Area/Main/Exploration">003B38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia</title><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F." last="Bansberg">Stephen F. Bansberg</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otorhinolaryngology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Krein Ones, Kari" sort="Krein Ones, Kari" uniqKey="Krein Ones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Speech Pathology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Section of Biostatistics, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-09">2004-09</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1075">1075</biblScope><biblScope unit="page" to="1079">1079</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4B96E5B2013281C64D41647F88951029FF0AB0DF</idno><idno type="DOI">10.1002/mds.20098</idno><idno type="ArticleID">MDS20098</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Bontoxilysin</term><term>Botulinum Toxins (administration & dosage)</term><term>Botulinum Toxins (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Injections</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neuromuscular Agents (administration & dosage)</term><term>Neuromuscular Agents (therapeutic use)</term><term>Safety</term><term>Severity of Illness Index</term><term>Spastic dysphonia</term><term>Vocal Cords (physiopathology)</term><term>Voice Disorders (diagnosis)</term><term>Voice Disorders (drug therapy)</term><term>Voice Disorders (physiopathology)</term><term>botulinum toxin type B</term><term>dystonia</term><term>spasmodic dysphonia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Voice Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Voice Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Vocal Cords</term><term>Voice Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Injections</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Dysphonie spasmodique</term><term>Système nerveux pathologie</term><term>Sécurité</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This single‐site, open‐label, dose‐finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT‐B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from −3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (± standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (±1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT‐B is safe and effective for the treatment of adductor spasmodic dysphonia. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name></region><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F." last="Bansberg">Stephen F. Bansberg</name><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name><name sortKey="Krein Ones, Kari" sort="Krein Ones, Kari" uniqKey="Krein Ones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4B96E5B2013281C64D41647F88951029FF0AB0DF
|texte= Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia
}}
| This area was generated with Dilib version V0.6.23. |  |